<DOC>
	<DOCNO>NCT00274638</DOCNO>
	<brief_summary>To demonstrate Telmisartan combine Hydrochlorothiazide ( MICARDIS® HCT ) superior Losartan Hydrochlorothiazide ( Hyzaar® ) lower blood pressure mild-moderate hypertensive .</brief_summary>
	<brief_title>PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide ( HCT ) ( 40/12.5 80/12.5 ) With Losartan/HCT ( 50/12.5 ) Using Ambulatory Blood Pressure Monitoring ( ABPM )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Ability provide write informed consent accordance GCP local legislation . 2 . Mildtomoderate hypertension define mean seated DBP &gt; = 95 mm Hg &lt; =l 109 mm Hg , measure manual cuff sphygmomanometer Visit 2 . 3 . Male Female &gt; = 18 year . 4 . Ability stop current antihypertensive therapy without risk patient ( investigator 's discretion ) . 5 . 24hour ABPM mean DBP &gt; = 85 mm Hg Visit 3 . 1 . Premenopausal woman ( last menstruation &lt; = 1 year prior sign informed consent ) surgically sterile , nursing , childbearing potential NOT practice acceptable method birth control , plan continue practice acceptable method throughout study . Acceptable method birth control include IUD , oral , implantable injectable contraceptive . No exception make . 2 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 A.M. 3 . Mean seat SBP &gt; = 180 mm Hg mean seat DBP &gt; = 110 mm Hg visit placebo runin phase . 4 . Known suspected secondary hypertension ( i.e . pheochromocytoma ) . 5 . Hepatic and/or renal dysfunction define follow laboratory parameter : ) SGPT ( ALT ) ( SGOT ) AST less two time upper limit normal range , b ) Serum creatinine great 2.3 mg/dL ( &gt; 203 mico mol/l ) . 6 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney . 7 . Biliary obstructive disorder . 8 . Clinically relevant sodium depletion , hypokalaemia hyperkalaemia . 9 . Uncorrected volume depletion . 10 . Primary aldosteronism . 11 . Hereditary fructose intolerance . 12 . Congestive heart failure ( NYHA functional class CHF IIIIV ) . 13 . Unstable angina within past 3 month prior sign inform consent form . 14 . Stroke within past 6 month prior sign inform consent form . 15 . Myocardial infarction cardiac surgery within past 3 month prior sign inform consent form . 16 . PTCA ( percutaneous transluminal coronary angioplasty ) within past 3 month prior sign inform consent form . 17 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator . 18 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 19 . Patients insulindependent diabetes mellitus whose diabetes stable control least past 3 month define HbA1C &gt; = 10 Percent . 20 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist . 21 . History drug alcohol dependency within 6 month prior sign inform consent form . 22 . Chronic administration medication know affect blood pressure , except medication allow protocol . 23 . Any investigational therapy within 1 month signing informed consent form . 24 . Known hypersensitivity component study drug ( placebo , telmisartan , hydrochlorothiazide losartan ) . 25 . Any clinical condition , opinion investigator would allow safe completion protocol safe administration trial medication . 26 . Concomitant use lithium cholestyramine colestipol resin ( potential drug interaction hydrochlorothiazide ) . 27 . History noncompliance prescribe medication . 28 . Inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>